PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-7.47%
Both companies show declining cash positions (-7.47% vs CRVO's -73.54%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-7.47%
Cash + STI yoy 0.5-0.75x CRVO's -12.76%. Martin Whitman would worry about lagging short-term reserves. Confirm debt coverage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-7.14%
0.5-0.75x CRVO's -11.23%. Martin Whitman might see risk if this hampers near-term financial flexibility.
-20.34%
Both CRVO and the company show zero PP&E (Net) Growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-20.34%
Below half of CRVO's -100.00%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
-7.25%
0.5-0.75x CRVO's -11.27%. Martin Whitman worries about slower asset growth than competitor. Is it strategy or constraint?
-4.95%
Less than half of CRVO's -14.17%. David Dodd sees a more disciplined AP approach or lower volume.
-36.48%
Higher Short-Term Debt Growth compared to CRVO's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-627.15%
Both CRVO and the company show zero Deferred Revenue (Current) Growth.
-89.58%
Less than half of CRVO's 58.40%. David Dodd sees fewer expansions in other current obligations.
-16.33%
Less than half of CRVO's 0.96%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-33.33%
Higher Total Non-Current Liabilities Growth compared to CRVO's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-16.34%
Less than half of CRVO's 0.96%. David Dodd sees far fewer liability expansions relative to competitor.
No Data
No Data available this quarter, please select a different quarter.
-2.01%
0.5-0.75x CRVO's -3.48%. Martin Whitman is wary of weaker retention or lower profitability.
100.00%
Higher AOCI Growth compared to CRVO's zero value, indicating worse performance.
-100.00%
Similar yoy changes to CRVO's -100.00%. Walter Schloss finds parallel equity item fluctuations.
-6.40%
0.5-0.75x CRVO's -12.30%. Martin Whitman is wary of lagging equity growth vs. competitor.
-7.25%
0.5-0.75x CRVO's -11.27%. Martin Whitman sees underexpansion or possible missed opportunities.
No Data
No Data available this quarter, please select a different quarter.
-36.45%
Higher Total Debt Growth compared to CRVO's zero value, indicating worse performance.
7.35%
Less than half of CRVO's 73.54%. David Dodd sees better deleveraging or stronger cash buildup than competitor.